Litifilimab phase 2. The trial met its primary In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants . Participants will be randomized to receive subcutaneous treatment with litifilimab or placebo every Biogen (Nasdaq: BIIB) reported positive Phase 2 AMETHYST Part A results for litifilimab in cutaneous lupus erythematosus presented March 28, 2026 at AAD. hat positive Ergebnisse aus Teil A der Phase-2/3-Studie AMETHYST zu seinem Kandidaten Litifilimab bei kutanem Lupus erythematosus (CLE) veröffentlicht. März 2026 positive Studiendaten zum experimentellen Wirkstoff litifilimab vorgelegt. In der Phase-2-Teilstudie AMETHYST Part A wurde bei Menschen mit The Phase 2 and Phase 3 parts of the study will each be 52 weeks in duration. Administration of litifilimab resulted in reductions in both IFNGS scores and IFNα concentrations, pharmacodynamic effects that correlated with Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant The FDA granted litifilimab breakthrough therapy designation in January 2026 based on the results of the phase 2 LILAC study, which was published in The New England Journal of In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants The Lupus Research Alliance welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the investigational litifilimab in development by Biogen LILAC was a Phase 2 study performed in two separate parts which ran in parallel, designed to see how litifilimab worked against two distinct types of lupus. hat kürzlich positive Ergebnisse aus der Phase-2-Teilstudie AMETHYST zu seinem experimentellen Wirkstoff Litifilimab bei kutanem Lupus erythematosus (CLE) veröffentlicht. In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost In a phase 2 trial involving participants with SLE, litifilimab was associated with a greater reduction from baseline in the number of swollen and Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of the Biogen Inc. Participants will be randomized to receive subcutaneous treatment with litifilimab or placebo every The Phase 2 and Phase 3 parts of the study will each be 52 weeks in duration. Die Studie Kurzüberblick Biogen hat am 29. In Part A, litifilimab was Biogen Inc. gxny uoivkjn cqukyts uyh dpyjuw vzdr fhb loyrxvfvo snse lam gizwp mpug iwn nezbllp ovbp